Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
MetLife has filed a Form 144 notice for the proposed sale of 1,024 shares of common stock with an aggregate market value of $81,879.04. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 27, 2025.
The securities to be sold were acquired in three separate purchases during 2013:
- 31 shares from Deutsche Bank on January 31, 2013
- 902 shares from Goldman Sachs on March 13, 2013
- 91 shares from Goldman Sachs on May 15, 2013
Recent trading activity shows that related entities have sold 1,256 shares in the past three months, totaling approximately $99,076.70 in gross proceeds. The filing was made by the MetLife 401(k) Plan Trust, which maintains an affiliate discretionary manager relationship with the issuer. The company has 671,297,826 shares outstanding.
MetLife has filed a Form 144/A notice for the proposed sale of securities, detailing planned transactions of 547 shares of common stock with an aggregate market value of $42,966.85 through Barclays Capital on the NYSE, scheduled for June 20, 2025.
The securities to be sold were originally acquired in two separate purchases from Deutsche Bank:
- 272 shares acquired on September 20, 2013
- 275 shares acquired on March 21, 2014
Recent trading activity in the past 3 months includes sales by various MetLife accounts totaling 686 shares with combined gross proceeds of $55,391.75. The largest transaction was by the MetLife 401k Plan Trust-Large Cap Equity Index, selling 335 shares for $27,590.60 on March 21, 2025. The company has approximately 671.3 million shares outstanding.
MetLife, Inc. (MET) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a planned sale of 27 shares of its common stock. The shares, carrying an aggregate market value of $2,120.85, are slated for sale on or about 20 June 2025 through Barclays Capital, 745 Seventh Ave, New York, NY 10019. The notice cites 671,297,826 shares outstanding, making the proposed transaction an immaterial fraction of total equity.
The filer also reported prior dispositions over the past three months totaling 686 shares for gross proceeds of roughly $55,392, executed on 21 March 2025 and 13 June 2025 by various MetLife-related accounts. The signing party affirms that no undisclosed material adverse information exists and that Rule 10b5-1 representations are satisfied.
MetLife, Inc. (MET) filed a Form 144 with the SEC disclosing a proposed sale of 360 common shares through Barclays Capital on or after 20 June 2025. The shares have an aggregate market value of $28,278, compared with the company’s 671,297,826 shares outstanding, representing less than 0.0001 % of total equity—an immaterial amount from an ownership-dilution perspective.
The filer originally acquired the shares on 29 May 2015 via a purchase from Goldman Sachs for cash. The notice affirms the seller’s representation that no undisclosed material adverse information is known.
Recent trading history: in the last three months, related MetLife accounts collectively sold 686 shares for $55,391.75 in gross proceeds. These transactions, combined with the planned 360-share disposition, remain de minimis relative to MetLife’s market capitalization and average daily trading volume. No financial performance data, strategic updates or governance changes accompany the filing.
Given the modest size and routine nature of the transaction, the filing is unlikely to influence MetLife’s valuation or trading dynamics.
MetLife, Inc. (MET) – Form 144 filing: The notice discloses a proposed sale of 101 common shares with an aggregate market value of $7,933.55. The shares were originally purchased on 12/17/2019 for cash and are slated to be sold through Barclays Capital on or about 06/20/2025 on the NYSE. The issuer has 671,297,826 shares outstanding, so the planned transaction represents less than 0.00002 % of equity. The filing also lists earlier sales by related MetLife accounts over the past three months totaling 686 shares for gross proceeds of $55,391.75. The signer affirms no undisclosed material adverse information and Rule 144 compliance.
MetLife Director Robert Glenn Hubbard acquired 964 shares of common stock on June 17, 2025, at a price of $77.85 per share, bringing his total direct beneficial ownership to 100,489 shares.
The acquisition was part of MetLife's non-management director compensation arrangements, where a portion of director retainer fees is paid in company common stock. Hubbard elected to defer the receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Key transaction details:
- Transaction type: Acquisition of non-derivative securities
- Total value of transaction: Approximately $75,047 (964 shares × $77.85)
- Ownership form: Direct
- Filing made as an individual reporting person